Why Is Merck & Stock Jumping Today? MRK +5.66% (May 25) — CHMP Keytruda Approval
Analysis Date: May 25, 2026. Merck & (MRK) shares jumped +5.66% today in a sharp move higher. Here's the reason for the Merck & share-price increase today — why is MRK stock up today?
- Ticker
- MRK
- Company
- Merck &
- Direction
- Up
- % Change
- +5.66%
- Date
- May 25, 2026
What happened
On May 25, 2026, Merck & Co. (MRK) stock rose approximately 5.66% after Europe's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion backing a Keytruda (pembrolizumab) combination therapy for bladder cancer.
- CHMP Endorsement: The CHMP's positive opinion is a critical regulatory milestone that typically leads to a formal European Commission approval, potentially expanding Keytruda's label in Europe.
- Bladder Cancer Indication: The new indication targets a significant patient population, adding to Keytruda's already extensive list of approved oncology uses.
- Keytruda's Importance: Keytruda is Merck's top-selling drug and a major driver of company revenue, making any label expansion a closely watched event for investors.
- Global Commercial Impact: A European approval would complement existing approvals in other markets, reinforcing Keytruda's position as a leading cancer immunotherapy worldwide.
This content is for educational and informational purposes only and is not investment advice.
Sources
Frequently asked
Why is Merck & stock up today?
Merck & (MRK) shares jumped +5.66% on May 25, 2026. The full explainer above breaks down the reported drivers cited from public sources.
Why did MRK surge today?
According to the cited sources, the move on May 25, 2026 was driven by the catalyst summarized in the explainer. See the Sources list below for primary references.
What caused Merck & stock to jump today?
On May 25, 2026, Merck & Co.
MRK stock news today?
Merck & shares closed up +5.66% on May 25, 2026 — a increase of 5.66% from the prior close.
Is this investment advice?
No. Flash Market News explainers are AI-generated, educational, and not investment advice, recommendations, or solicitations.
AI-generated explainer from verified sources; not investment advice.